SEC 13F Intelligence

Managers / Q2 2022 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$166M
Q2 2022
Positions
110
Filings on Record
30
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Highvista Strategies LLC reported $166M in U.S.-listed holdings across 110 positions for Q2 2022.

Its largest position, DELL, represents 9.9% of the portfolio.

Compared with Q1 2022, the fund opened 39 new positions and exited 15.

Portfolio Metrics

Turnover
+21.7%
vs prior filed quarter
Top-10 Concentration
+40.9%
share of reported value
Largest Position
+9.9%
Dell Technologies
New / Exited
39 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.1%Other: 9.9%ADR: 3.2%ETP: 2.8%
  • Common Stock · 84.1% · $139M
  • Other · 9.9% · $16M
  • ADR · 3.2% · $5M
  • ETP · 2.8% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ISHARES TRNEW+23.8K23.8K+$3M$3M
TGNATEGNA INCNEW+144.0K144.0K+$3M$3M
TWTRUSDTWITTER INCNEW+64.0K64.0K+$2M$2M
KPTIEURKARYOPHARM THERAPEUTICS INCNEW+250.4K250.4K+$1M$1M
MSFTMICROSOFT CORPNEW+4.0K4.0K+$1M$1M
KRYSKRYSTAL BIOTECH INCNEW+12.2K12.2K+$803,000$803,000
CEREVEL THERAPEUTICS HLDNG INEW+28.4K28.4K+$752,000$752,000
ARQTARCUTIS BIOTHERAPEUTICS INCNEW+34.5K34.5K+$734,000$734,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C9.92%$16M355.4K
2MAMASTERCARD INCORPORATEDhistory →CL A7.05%$12M37.0K
3VVISA INChistory →COM CL A5.14%$9M43.3K
4FISVFISERV INChistory →COM4.64%$8M86.3K
5MSD ACQUISITION CORPUNIT 03/25/20262.98%$5M500.0K
6KURAKURA ONCOLOGY INChistory →COM2.41%$4M217.9K
7CHNGUSDCHANGE HEALTHCARE INChistory →COM2.26%$4M162.1K
8PYPLPAYPAL HLDGS INChistory →COM2.25%$4M53.3K
9COHREURCOHERENT INChistory →COM2.19%$4M13.6K
10ISHARES TRRUS 1000 VAL ETF2.09%$3M23.8K
11CPNGCOUPANG INChistory →CL A1.97%$3M256.3K
12ATVIEURACTIVISION BLIZZARD INChistory →COM1.88%$3M40.0K
13CTXSEURCITRIX SYS INChistory →COM1.84%$3M31.4K
14ACRSACLARIS THERAPEUTICS INChistory →COM1.83%$3M217.5K
15TGNATEGNA INChistory →COM1.82%$3M144.0K
16TURNING POINT THERAPEUTICS ICOM1.79%$3M39.4K
17FT2FIRST HORIZON CORPORATIONhistory →COM1.79%$3M135.4K
18FATEFATE THERAPEUTICS INChistory →COM1.78%$3M118.8K
19CYTKCYTOKINETICS INChistory →COM NEW1.60%$3M67.5K
20BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.53%$3M151.2K
21TVTXTRAVERE THERAPEUTICS INChistory →COM1.52%$3M104.2K
22TWTRUSDTWITTER INChistory →COM1.44%$2M64.0K
23GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM1.43%$2M74.3K
24RPTXREPARE THERAPEUTICS INChistory →COM1.29%$2M152.6K
25APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.26%$2M46.1K
26CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.18%$2M200.0K
27NOVOCURE LTDORD SHS1.17%$2M28.0K
28RLAYRELAY THERAPEUTICS INChistory →COM1.15%$2M113.3K
29RCUSARCUS BIOSCIENCES INChistory →COM1.10%$2M71.7K
30IDYAIDEAYA BIOSCIENCES INChistory →COM1.09%$2M130.4K
31BMEABIOMEA FUSION INChistory →COM1.05%$2M144.7K
32DYNDYNE THERAPEUTICS INChistory →COM1.00%$2M241.9K
33GENERATION BIO COCOM0.99%$2M249.0K
34CYMABAY THERAPEUTICS INCCOM0.70%$1M395.3K
35KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.68%$1M250.4K
36DBCINVESCO DB COMMDY INDX TRCKUNIT0.68%$1M42.4K
37MSFTMICROSOFT CORPCOM0.62%$1M4.0K
38AM6AMICUS THERAPEUTICS INCCOM0.59%$969,00090.2K
39BBIOBRIDGEBIO PHARMA INCCOM0.58%$962,000105.9K
40MERUS N VCOM0.55%$916,00040.5K
41CHINOOK THERAPEUTICS INCCOM0.54%$889,00050.8K
42IMGNEURIMMUNOGEN INCCOM0.52%$863,000191.7K
43EWTXEDGEWISE THERAPEUTICS INCCOM0.50%$824,000103.5K
44ARGXARGENX SESPONSORED ADR0.49%$816,0002.2K
45UTHUNITED THERAPEUTICS CORP DELCOM0.49%$813,0003.5K
46BEAMBEAM THERAPEUTICS INCCOM0.49%$812,00021.0K
47GOSSGOSSAMER BIO INCCOM0.49%$810,00096.8K
48KRYSKRYSTAL BIOTECH INCCOM0.48%$803,00012.2K
49CEREVEL THERAPEUTICS HLDNG ICOM0.45%$752,00028.4K
50AMARIN CORP PLCSPONS ADR NEW0.45%$746,000500.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.